Methods for slowing senescence and treating and preventing diseases associated with senescence
AssigneeVoyager Pharmaceutical Corporation
InventorRichard L. Bowen
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method for slowing, preventing or delaying senescence or treating or preventing a disease associated with senescence by administering a therapeutically effective amount of at least one physiological agent that decreases or regulates the blood level, production, function or activity of LH or FSH, or that decreases or regulates the production or activity of activin, or that increases or regulates the blood level, production, function, or activity of inhibin or follistatin.
Claims186
A method of slowing, preventing or delaying senescence in a subject, comprising:
- administering to the subject a therapeutically effective amount of an agent that decreases or regulates blood level, production, function or activity of LH or FSH;
- said agent comprising one or more of the following, or a physiologically acceptable analog, metabolite, precursor or salt thereof:
- GnRH;
- leuprolide;
- triptorelin;
- buserelin;
- nafarelin;
- desorelin;
- histrelin;
- goserelin;
- follistatin;
- a compound that stimulates the production of follistatin;
- a GnRH antagonist;
- a GnRH receptor blocker;
- citrorelix;
- abberelix;
- a vaccine or antibody that stimulates the production of antibodies that inhibit the activity of any of LH, FSH, or GnRH;
- a vaccine or antibody that stimulates the production of antibodies that block a LH receptor, a FSH receptor, or a GnRH receptor;
- a compound that regulates expression of a LH or FSH receptor;
- or a compound that regulates post-receptor signaling of a LH or FSH receptor.
A method of slowing, preventing or delaying senescence in a subject, comprising:
- administering to the subject a therapeutically effective amount of an agent that decreases or regulates blood level, production, function or activity of activin.
A method of slowing, preventing or delaying senescence in a subject, comprising:
- administering to the subject a therapeutically effective amount of an agent that increases or regulates blood level, production, function or activity of follistatin.
A method of treating or preventing a disease associated with senescence in a subject, comprising:
- administering to the subject a therapeutically effective amount of an agent that decreases or regulates blood level, production, function or activity of LH or FSH;
- said agent comprising one or more of the following, or a physiologically acceptable analog, metabolite, precursor or salt thereof:
- GnRH;
- leuprolide;
- triptorelin;
- buserelin;
- nafarelin;
- desorelin;
- histrelin;
- goserelin;
- follistatin;
- a compound that stimulates the production of follistatin;
- a GnRH antagonist;
- a GnRH receptor blocker;
- citrorelix;
- abberelix;
- a vaccine or antibody that stimulates the production of antibodies that inhibit the activity of any of LH, FSH, or GnRH;
- a vaccine or antibody that stimulates the production of antibodies that block a LH receptor, a FSH receptor, or a GnRH receptor;
- a compound that regulates expression of a LH or FSH receptor;
- or a compound that regulates post-receptor signaling of a LH or FSH receptor.
A method of treating or preventing a disease associated with senescence in a subject, comprising:
- administering to the subject a therapeutically effective amount of an agent that decreases or regulates blood level, production, function or activity of activin.
A method of treating or preventing a disease associated with senescence in a subject, comprising:
- administering to the subject a therapeutically effective amount of an agent that increases or regulates blood level, production, function or activity of follistatin.
A method of preventing or slowing proliferation of monocytes, macrophages, smooth muscle cells, endothelial cells, fibroblasts, or lymphocytes in a subject, comprising:
- administering to the subject a therapeutically effective amount of an agent that decreases or regulates blood level, production, function or activity of LH or FSH;
- said agent comprising one or more of the following, or a physiologically acceptable analog, metabolite, precursor or salt thereof:
- GnRH;
- leuprolide;
- triptorelin;
- buserelin;
- nafarelin;
- desorelin;
- histrelin;
- goserelin;
- follistatin;
- a compound that stimulates the production of follistatin;
- a GnRH antagonist;
- a GnRH receptor blocker;
- citrorelix;
- abberelix;
- a vaccine or antibody that stimulates the production of antibodies that inhibit the activity of any of LH, FSH, or GnRH;
- a vaccine or antibody that stimulates the production of antibodies that block a LH receptor, a FSH receptor, or a GnRH receptor;
- a compound that regulates expression of a LH or FSH receptor;
- or a compound that regulates post-receptor signaling of a LH or FSH receptor.
A method of preventing or slowing proliferation of monocytes, macrophages, smooth muscle cells, endothelial cells, fibroblasts, or lymphocytes in a subject, comprising:
- administering to the subject a therapeutically effective amount of an agent that decreases or regulates blood level, production, function or activity of activin.
A method of preventing or slowing proliferation of monocytes, macrophages, smooth muscle cells, endothelial cells, fibroblasts, or lymphocytes in a subject, comprising:
- administering to the subject a therapeutically effective amount of an agent that increases or regulates blood level, production, function or activity of follistatin.
A method of preventing or slowing proliferation of neuronal cells in a subject, comprising:
- administering to the subject a therapeutically effective amount of an agent that decreases or regulates blood level, production, function or activity of LH or FSH;
- said agent comprising one or more of the following, or a physiologically acceptable analog, metabolite, precursor or salt thereof:
- GnRH;
- leuprolide;
- triptorelin;
- buserelin;
- nafarelin;
- desorelin;
- histrelin;
- goserelin;
- follistatin;
- a compound that stimulates the production of follistatin;
- a GnRH antagonist;
- a GnRH receptor blocker;
- citrorelix;
- abberelix;
- a vaccine or antibody that stimulates the production of antibodies that inhibit the activity of any of LH, FSH, or GnRH;
- a vaccine or antibody that stimulates the production of antibodies that block a LH receptor, a FSH receptor, or a GnRH receptor;
- a compound that regulates expression of a LH or FSH receptor;
- or a compound that regulates post-receptor signaling of a LH or FSH receptor.
A method of preventing or slowing proliferation of neuronal cells in a subject, comprising:
- administering to the subject a therapeutically effective amount of an agent that decreases or regulates blood level, production, function or activity of activin.
A method of preventing or slowing proliferation of neuronal cells in a subject, comprising:
- administering to the subject a therapeutically effective amount of an agent that increases or regulates blood level, production, function or activity of follistatin.
A method of preventing or slowing proliferation of cartilage cells, synovial intima cells, fibroblasts, or endothelial cells in a subject, comprising:
- administering to the subject a therapeutically effective amount of an agent that decreases or regulates blood level, production, function or activity of LH or FSH;
- said agent comprising one or more of the following, or a physiologically acceptable analog, metabolite, precursor or salt thereof:
- GnRH;
- leuprolide;
- triptorelin;
- buserelin;
- nafarelin;
- desorelin;
- histrelin;
- goserelin;
- follistatin;
- a compound that stimulates the production of follistatin;
- a GnRH antagonist;
- a GnRH receptor blocker;
- citrorelix;
- abberelix;
- a vaccine or antibody that stimulates the production of antibodies that inhibit the activity of any of LH, FSH, or GnRH;
- a vaccine or antibody that stimulates the production of antibodies that block a LH receptor, a FSH receptor, or a GnRH receptor;
- a compound that regulates expression of a LH or FSH receptor;
- or a compound that regulates post-receptor signaling of a LH or FSH receptor.
A method of preventing or slowing proliferation of cartilage cells, synovial intima cells, fibroblasts, or endothelial cells in a subject, comprising:
- administering to the subject a therapeutically effective amount of an agent that decreases or regulates blood level, production, function or activity of activin.
A method of preventing or slowing proliferation of cartilage cells, synovial intima cells, fibroblasts, or endothelial cells in a subject, comprising:
- administering to the subject a therapeutically effective amount of an agent that increases or regulates blood level, production, function or activity of follistatin.
A method of preventing or slowing proliferation of myelogenous cells in a subject, comprising:
- administering to the subject a therapeutically effective amount of an agent that decreases or regulates blood level, production, function or activity of LH or FSH;
- said agent comprising one or more of GnRH;
- leuprolide;
- triptorelin;
- buserelin;
- nafarelin;
- desorelin;
- histrelin;
- goserelin;
- follistatin;
- a compound that stimulates the production of follistatin;
- a GnRH antagonist;
- a GnRH receptor blocker;
- citrorelix;
- abberelix;
- a vaccine or antibody that stimulates the production of antibodies that inhibit the activity of any of LH, FSH, or GnRH;
- a vaccine or antibody that stimulates the production of antibodies that block a LH receptor, a FSH receptor, or a GnRH receptor;
- a compound that regulates expression of a LH or FSH receptor;
- a compound that regulates post-receptor signaling of a LH or FSH receptor;
- or a physiologically acceptable analog, metabolite, precursor or salt thereof.
A method of preventing or slowing proliferation of myelogenous cells in a subject, comprising:
- administering to the subject a therapeutically effective amount of an agent that decreases or regulates blood level, production, function or activity of activin.
A method of preventing or slowing proliferation of myclogenous cells in a subject, comprising:
- administering to the subject a therapeutically effective amount of an agent that increases or regulates blood level, production, function or activity of follistatin.
A method of preventing or slowing proliferation of osteoclasts in a subject, comprising:
- administering to the subject a therapeutically effective amount of an agent that decreases or regulates blood level, production, function or activity of LH or FSH;
- said agent comprising one or more of GnRH;
- leuprolide;
- triptorelin;
- buserelin;
- nafarelin;
- desorelin;
- histrelin;
- goserelin;
- follistatin;
- a compound that stimulates the production of follistatin;
- a GnRH antagonist;
- a GnRH receptor blocker;
- citrorelix;
- abberelix;
- a vaccine that stimulates the production of antibodies that inhibit the activity of any of LH, FSH, or GnRH;
- a vaccine that stimulates the production of antibodies that block a LH receptor, a FSH receptor, or a GnRH receptor;
- or a physiologically acceptable analog, metabolite or salt thereof.
A method of preventing or slowing proliferation of osteoclasts in a subject, comprising:
- administering to the subject a therapeutically effective amount of an agent that decreases or regulates blood level, production, function or activity of activin.
A method of preventing or slowing proliferation of osteoclasts in a subject, comprising:
- administering to the subject a therapeutically effective amount of an agent that increases or regulates blood level, production, function or activity of follistatin.
A method of increasing or promoting proliferation of osteoblasts in a subject, comprising:
- administering to the subject a therapeutically effective amount of an agent that decreases or regulates blood level, production, function or activity of LH or FSH;
- said agent comprising one or more of GnRH;
- leuprolide;
- triptorelin;
- buserelin;
- nafarelin;
- desorelin;
- histrelin;
- goserelin;
- follistatin;
- a compound that stimulates the production of follistatin;
- a GnRH antagonist;
- a GnRH receptor blocker;
- citrorelix;
- abberelix;
- a vaccine that stimulates the production of antibodies that inhibit the activity of any of LH, FSH, or GnRH;
- a vaccine that stimulates the production of antibodies that block a LH receptor, a FSH receptor, or a GnRH receptor;
- or a physiologically acceptable analog, metabolite or salt thereof.
A method of increasing or promoting proliferation of osteoblasts in a subject, comprising:
- administering to the subject a therapeutically effective amount of an agent that decreases or regulates blood level, production, function or activity of activin.
A method of increasing or promoting proliferation of osteoblasts in a subject, comprising:
- administering to the subject a therapeutically effective amount of an agent that increases or regulates blood level, production, function or activity of follistatin.
A method of preventing or slowing colorectal polyp formation in a subject, comprising:
- administering to the subject a therapeutically effective amount of an agent that decreases or regulates blood level, production, function or activity of LH or FSH;
- said agent comprising one or more of GnRH;
- leuprolide;
- triptorelin;
- buserelin;
- nafarelin;
- desorelin;
- histrelin;
- goserelin;
- follistatin;
- a compound that stimulates the production of follistatin;
- a GnRH antagonist;
- a GnRH receptor blocker;
- citrorelix;
- abberelix;
- a vaccine that stimulates the production of antibodies that inhibit the activity of any of LH, FSH, or GnRH;
- a vaccine that stimulates the production of antibodies that block a LH receptor, a FSH receptor, or a GnRH receptor;
- or a physiologically acceptable analog, metabolite or salt thereof.
A method of preventing or slowing colorectal polyp formation in a subject, comprising:
- administering to the subject a therapeutically effective amount of an agent that decreases or regulates blood level, production, function or activity of activin.
A method of preventing or slowing colorectal polyp formation in a subject, comprising:
- administering to the subject a therapeutically effective amount of an agent that increases or regulates blood level, production, function or activity of follistatin.
A method of preventing or slowing proliferation of cells of colorectal tissue in a subject, comprising:
- administering to the subject a therapeutically effective amount of an agent that decreases or regulates blood level, production, function or activity of LH or FSH;
- said agent comprising one or more of GnRH;
- leuprolide;
- triptorelin;
- buserelin;
- nafarelin;
- desorelin;
- histrelin;
- goserelin;
- follistatin;
- a compound that stimulates the production of follistatin;
- a GnRH antagonist;
- a GnRH receptor blocker;
- citrorelix;
- abberelix;
- a vaccine that stimulates the production of antibodies that inhibit the activity of any of LH, FSH, or GnRH;
- a vaccine that stimulates the production of antibodies that block a LH receptor, a FSH receptor, or a GnRH receptor;
- or a physiologically acceptable analog, metabolite or salt thereof.
A method of preventing or slowing proliferation of cells of colorectal tissue in a subject, comprising:
- administering to the subject a therapeutically effective amount of an agent that decreases or regulates blood level, production, function or activity of activin.
A method of preventing or slowing proliferation of cells of colorectal tissue in a subject, comprising:
- administering to the subject a therapeutically effective amount of an agent that increases or regulates blood level, production, function or activity of follistatin.
A method of decreasing or regulating a mitogenic index in a subject, comprising:
- administering to the subject a therapeutically effective amount of an agent that decreases or regulates blood level, production, function or activity of LH or FSH;
- said agent comprising one or more of the following, or a physiologically acceptable analog, metabolite, precursor or salt thereof:
- GnRH;
- leuprolide;
- triptorelin;
- buserelin;
- nafarelin;
- desorelin;
- histrelin;
- goserelin;
- follistatin;
- a compound that stimulates the production of follistatin;
- a GnRH antagonist;
- a GnRH receptor blocker;
- citrorelix;
- abberelix;
- a vaccine or antibody that stimulates the production of antibodies that inhibit the activity of any of LH, FSH, or GnRH;
- a vaccine or antibody that stimulates the production of antibodies that block a LH receptor, a FSH receptor, or a GnRH receptor;
- a compound that regulates expression of a LH or FSH receptor;
- or a compound that regulates post-receptor signaling of a LH or FSH receptor.
A method of decreasing or regulating a mitogenic index in a subject, comprising:
- administering to the subject a therapeutically effective amount of an agent that decreases or regulates blood level, production, function or activity of activin.
A method of decreasing or regulating a mitogenic index in a subject, comprising:
- administering to the subject a therapeutically effective amount of an agent that increases or regulates blood level, production, function or activity of follistatin.
A method of inhibiting shortening of telomeres in a subject, comprising:
- administering to the subject a therapeutically effective amount of an agent that decreases or regulates blood level, production, function or activity of LH or FSH;
- said agent comprising one or more of the following, or a physiologically acceptable analog, metabolite, precursor or salt thereof:
- GnRH;
- leuprolide;
- triptorelin;
- buserelin;
- nafarelin;
- desorelin;
- histrelin;
- goserelin;
- follistatin;
- a compound that stimulates the production of follistatin;
- a GnRH antagonist;
- a GnRH receptor blocker;
- citrorelix;
- abberelix;
- a vaccine or antibody that stimulates the production of antibodies that inhibit the activity of any of LH, FSH, or GnRH;
- a vaccine or antibody that stimulates the production of antibodies that block a LH receptor, a FSH receptor, or a GnRH receptor;
- a compound that regulates expression of a LH or FSH receptor;
- or a compound that regulates post-receptor signaling of a LH or FSH receptor.
A method of inhibiting shortening of telomeres in a subject, comprising:
- administering to the subject a therapeutically effective amount of an agent that decreases or regulates blood level, production, function or activity of activin.
A method of inhibiting shortening of telomeres in a subject, comprising:
- administering to the subject a therapeutically effective amount of an agent that increases or regulates blood level, production, function or activity of follistatin.
A method of preventing or treating brain damage associated with acute brain injury in a subject, comprising:
- administering to the subject a therapeutically effective amount of an agent that decreases or regulates blood level, production, function or activity of LH or FSH;
- said agent comprising one or more of the following, or a physiologically acceptable analog, metabolite, precursor or salt thereof:
- GnRH;
- leuprolide;
- triptorelin;
- buserelin;
- nafarelin;
- desorelin;
- histrelin;
- goserelin;
- follistatin;
- a compound that stimulates the production of follistatin;
- a GnRH antagonist;
- a GnRH receptor blocker;
- citrorelix;
- abberelix;
- a vaccine or antibody that stimulates the production of antibodies that inhibit the activity of any of LH, FSH, or GnRH;
- a vaccine or antibody that stimulates the production of antibodies that block a LH receptor, a FSH receptor, or a GnRH receptor;
- a compound that regulates expression of a LH or FSH receptor;
- or a compound that regulates post-receptor signaling of a LH or FSH receptor.
A method of preventing or treating brain damage associated with acute brain injury in a subject, comprising:
- administering to the subject a therapeutically effective amount of an agent that decreases or regulates blood level, production, function or activity of activin.
A method of preventing or treating brain damage associated with acute brain injury in a subject, comprising:
- administering to the subject a therapeutically effective amount of an agent that increases or regulates blood level, production, function or activity of follistatin.
A method of slowing, preventing or delaying senescence in a subject, comprising
- administering to the subject a therapeutically effective amount of an agent comprising one or more of the following, or a physiologically acceptable analog, metabolite, precursor, or salt thereof:
- taxol;
- vitamin A;
- hydroxyurea;
- colchicines;
- a cholesterol lowering drug;
- or a vaccine or antibody that stimulates the production of antibodies that blocks the activity of a protein associated with promoting cell cycling.
A method of treating or preventing brain damage associated with acute brain injury in a subject, comprising
- administering to the subject a therapeutically effective amount of an agent comprising one or more of the following, or a physiologically acceptable analog, metabolite, precursor, or salt thereof:
- taxol;
- vitamin A;
- hydroxyurea;
- colchicines;
- a cholesterol lowering drug;
- or a vaccine or antibody that stimulates the production of antibodies that blocks the activity of a protein associated with promoting cell cycling.
A method of treating or preventing atherosclerosis in a subject, comprising
- administering to the subject a therapeutically effective amount of an agent comprising one or more of the following, or a physiologically acceptable analog, metabolite, precursor, or salt thereof:
- taxol;
- vitamin A;
- hydroxyurea;
- colchicines;
- a cholesterol lowering drug;
- or a vaccine or antibody that stimulates the production of antibodies that blocks the activity of a protein associated with promoting cell cycling.
A method of treating or preventing osteoporosis in a subject, comprising
- administering to the subject a therapeutically effective amount of an agent comprising one or more of the following, or a physiologically acceptable analog, metabolite, precursor, or salt thereof:
- taxol;
- vitamin A;
- hydroxyurea;
- colchicines;
- a cholesterol lowering drug;
- or a vaccine or antibody that stimulates the production of antibodies that blocks the activity of a protein associated with promoting cell cycling.
A method of preventing or inhibiting an upregulation of the cell cycle in a subject comprising:
- administering to the subject a therapeutically effective amount of at least one physiological agent that decreases or regulates blood level, production, function or activity of LH or FSH;
- said agent comprising one or more of the following, or a physiologically acceptable analog, metabolite, precursor or salt thereof:
- GnRH;
- leuprolide;
- triptorelin;
- buserelin;
- nafarelin;
- desorelin;
- histrelin;
- goserelin;
- follistatin;
- a compound that stimulates the production of follistatin;
- a GnRH antagonist;
- a GnRH receptor blocker;
- citrorelix;
- abberelix;
- a vaccine or antibody that stimulates the production of antibodies that inhibit the activity of any of LH, FSH, or GnRH;
- a vaccine or antibody that stimulates the production of antibodies that block a LH receptor, a FSH receptor, or a GnRH receptor;
- a compound that regulates expression of a LH or FSH receptor;
- or a compound that regulates post-receptor signaling of a LH or FSH receptor.
A method of preventing or inhibiting an upregulation of the cell cycle in a subject comprising:
- administering to the subject a therapeutically effective amount of at least one physiological agent that decreases or regulates blood level, production, function or activity of activin.
A method of preventing or inhibiting an upregulation of the cell cycle in a subject comprising:
- administering to the subject a therapeutically effective amount of at least one physiological agent that increases or regulates blood level, production, function or activity of follistatin.
A method of determining the mitogenic index in a subject, comprising:
- providing a test sample comprising a first plurality of cells from a standardized cell line in a standard growth medium;
- collecting a tissue sample from the subject;
- applying the tissue sample to the test sample to form a combined sample;
- measuring cell proliferation of the combined sample;
- providing a control sample comprising a second plurality of cells from the standardized cell line in the standard growth medium;
- measuring cell proliferation of the control sample;
- and
- comparing the cell proliferation of the control sample and the cell proliferation of the combined sample.
A system for measuring a mitogenic index in a subject comprising:
- a test sample comprising a first plurality of cells from a standardized cell line in a standard growth medium;
- means for collecting a tissue sample from the subject;
- means for applying the tissue sample to the test sample to form a combined sample;
- means for measuring cell proliferation of the combined sample;
- a control sample comprising a second plurality of cells from the standardized cell line in the standard growth medium;
- means for measuring cell proliferation of the control sample;
- and
- means for comparing the cell proliferation of the control sample and the cell proliferation of the combined sample.
Dependencies are inferred from the claim text.